More Details Emerge on Medivation’s XTANDI in Prostate Cancer
Insights - The data were presented at the 2015 European Association of Urology Congress.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
MEI Pharma’s Pracinostat Fails Latest Trial
Insights - A combination of MEI Pharma’s (MEIP) Pracinostat and the chemotherapy Vidaza (azacitidine) failed to improve remission rates compared to azacitidine alone in patients with Myelodysplastic Syndrome (MDS), … Continue Reading
Read now
A Roundup of our Top Stories in Healthcare from the Week
Biogen Idec Meets Investor Expectations with Early Alzheimer’s Drug
Insights - Even after adding $30 billion in market value over the last four months, shares of Biogen Idec (BIIB) moved higher on Friday morning with the release of … Continue Reading
Read now
Updating on a Number of Our Recent ‘Smid-Cap’ Picks
Research - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read now
Retrophin’s Busy Week: A Financing, a Drug Approval and a Valuable FDA Voucher
Insights - Just a day after Retrophin (RTRX) announced a $100 million financing the U.S. FDA has approved its Cholbam (cholic acid) for pediatric and adult patients with bile … Continue Reading
Read now
Esperion‘s Oral Cholesterol Drug Passes Latest Hurdle
Insights - Esperion Therapeutics, Inc. (ESPR) on released positive Phase 2b results for ETC-1002, its novel, oral cholesterol lowering therapy.
Read now